Jordan, Virgil Craig
Vice President and Research Director of Medical Sciences


University of Leeds, England B. Sc. 1969 Pharmacy
University of Leeds, England Ph.D. 1972 Pharmacology
Worcester Foundation, Shrewsbury, MA Postdoc 1972-1973 Antiestrogens
University of Leeds, England D.Sc. 1986 Antiestrogens



1973-74 Visiting Scientist, Worcester Foundation for Experimental Biology, Shrewsbury, MA
1974-78 Lecturer in Pharmacology, University of Leeds, Tenure, 1977
1979-80 Head, Endocrinology Unit, Ludwig Institute for Cancer Research, Berne, Switzerland
1980-81 Assistant Professor, Human Oncology and Pharmacology, University of Wisc., Madison, WI
1981-85 Associate Professor, Human Oncology and Pharmacology, University of Wisc., Madison, WI
1985-93 Professor, Human Oncology and Pharmacology, University of Wisconsin, Madison, WI
1987-93 Director, Breast Cancer Program, University of Wisconsin Comprehensive Cancer Center, WI
1993-95 Visiting Professor, Human Oncology and Pharmacology, University of Wisconsin, Madison, WI
1994-present Director, Breast Cancer Research Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
1993-2004 Professor, Molecular Pharmacology and Biological Chemistry, Northwestern University, Chicago, IL
1999-2004 Diana, Princess of Wales Professor of Cancer Research, Northwestern University, Chicago, IL
2005-present Vice President and Research Director of Medical Sciences, Fox Chase Cancer Center, Philadelphia, PA, Alfred G. Knudson Chair of Cancer Research


1989 AACR (Cain Award), 1992 Komen Found. Brinker Int. Award, 1993 Brit. Pharm. Soc. (Gaddum Award), 1993 ASPET Award Therapeutics in Human Disease, 1993 Cameron Prize (Edinburgh Univ.), 1995 Excellence in Medicine (Am./It. Found. NY), 1997 Cino Del Duca Award (Paris), 2000 Fellowship/Medal Univ. Coll. Dublin, 2000 Strang Award (Cornell), 2001 24th Bristol Myers Squibb Award Distinguished Achievement in Cancer Res., 2001 EIO Lifetime Achievement Award in Breast Cancer Research (Milan), 2001 Doctors of Medicine and Science Degrees (honorary) Leeds Univ., Univ. Mass., respectively, 2002 American Cancer Society Medal of Honor. 2002 Officer of the Most Excellent Order of the British Empire (OBE) for services to International Breast Cancer Research, 2002 AACR Inaugural Dorothy P. Landon Prize in Translational Research (with E.V. Jensen) for extraordinary accomplishment in translational research, 2003-4 Royal Society of Chemistry: Third Sosnovsky Award in Cancer Therapy. Recognizes landmark achievements in the medicinal chemistry of cancer diseases. 2003 The Charles F. Kettering Prize for the most outstanding recent contribution to cancer treatment (General Motors Cancer Research Foundation).

Selected peer-review publications: (out of approximately 250 publications)

Gottardis, M. M. and Jordan, V.C. (1988) Development of tamoxifen-stimulated growth of MCF 7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 48:5183-5187.

Gottardis, M. M., Wagner, R.J., Borden, E. C., and Jordan, V.C. (1989) Differential ability of antiestrogens t to stimulate breast cancer cell (MCF 7) growth in vivo and in vitro. Cancer Research 49:4765 4769.

Wolf, D. M., Langan-Fahey, S.M., Parker, C. J., McCague, R. and Jordan, V.C. (1993) Investigation of the mechanism of tamoxifen stimulated breast tumor growth with non-isomerizable analogs of tamoxifen and metabolites. Journal of the National Cancer Institute 85(10):806-812.

Wolf, D. M. and Jordan, V.C. (1994) Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Research and Treatment. 31:117-127. Sarkaria, J.N., Fowler, J.F., Lindstrom, M.J., Jordan, V.C. and Mulcahy, R.T. (1995).

The decreased influence of overall treatment time on the response of human breast tumor xerografts following prolongation of the potential doubling time (Tpot). International Journal of Radiation Oncology, Biology and Physics 31:833-840.

Pink, J.J. and Jordan V.C. (1996) Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Research 56:2321-2330.
Pink J.J., Bilimoria M. M., Assikis V.J., and Jordan V.C. (1996) Irreversible loss of the estrogen receptor in T47D breast cancer cells following prolonged estrogen deprivation. British Journal of Cancer 74:1227-1236.

O’Regan, R., Cisneros, A., England, G.M., MacGregor, J.I., Muenzner, H.D., Assikis, V.J., Bilimoria, M.M.,Piette, M., Dragan, Y.P., Pitot, H.C., Chatterton, R. and Jordan, V.C. (1998) Effects of the antiestrogens, tamoxifen, toremifene and ICI 182,780 on endometrial cancer growth in vivo. Journal of the National Cancer Institute 90:1552-1558.

Cummings, S.R., Eckert,S., Krueger, K.A., Grady, D., Powles, T.J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N.H., Morrow, M., Lippman, M.E. Black, D., Glusman, J.E., Costa, A., and Jordan, V.C. 1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Journal of the American Medical Association 281:2189-2197.

Yao, K., Lee E.-S., Bentrem D. J., England G., Schafer J.I.M., O’Regan R., and Jordan V. C. (2000) Antitumor action of physiologic estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clinical Cancer Research 6(5):2028-36

MacGregor-Schafer, J. I., Lee, E-S., O’Regan, R. M., Yao, K. and Jordan, V. C. (2000) Rapid development of tamoxifen stimulated mutant p53 breast tumors (T47D) in athymic mice. Clinical Cancer Research, 6:4373-80

Bentrem, D. J., Dardes, R. C., Liu, H. MacGregor-Schafer, J. I., Zapf, J. W. and Jordan, V. C. (2001) Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 142:838-846.

Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W., Stepan, J. J., Powles, T. J., Morrow, M., Costa, A., Silfen, S. L., Walls, E. L., Schmitt, H., Muchmore, D. B., and Jordan, V. C. (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Research and Treatment 65: 125-134.

Lee E. S., MacGregor-Schafer J. I., Yao K., England G., O’Regan R. M., De Los Reyes A., and Jordan V. C. (2000) Cross resistance of triphenylethylene-type antiestrogen but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clinical Cancer Research 6:4893-9.

Fournier, D.B., Chisamore, M., Lurain, J.R., Rademaker, A.W., Jordan, V.C., and Tonetti, D.A. (2001) Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role of AP-1 mediated proliferation of ER negative endometrial cancer. Gynecological Oncology 81:366-372

Liu, H., Lee, E. S., De Los Reyes, A., Zapf, J. W., and Jordan, V. C. (2001) Silencing and reactivation of the selective estrogen receptor modulator (SERM)-ER alpha complex Cancer Research 61:3632-3639

MacGregor Schafer, J., Lee, E., Dardes, R., Bentrem, D., O’Regan, R., De Los Reyes, A., Jordan, V. C., (2001) Analysis of cross resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts, Clinical Cancer Research 7:2505-12.

Chisamore, M.J., Ahmed, Y., Bentrem, D., Jordan, V.C., Tonetti, D.A. (2001) A novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha. Clinical Cancer Research 7: 3156-3165.

Jordan VC, MacGregor Schafer, J., Levenson, A.S., Liu, H., Pease, K.M., Simons, L.A., and Zapf, J. W.(2001) Molecular classification of estrogens. Cancer Research 61:6619-6623.

Dardes RC, Bentrem, D., O'Regan, R.M., MacGregor Shafer, J., Jordan, V.C. (2001) Effects of the new selective estrogen receptor modulator LY353381.HCI (arzoxifene) on human endometrial cancer growth in athymic mice. Clinical Cancer Research 7:4149-4155.

O'Regan, R.M., Gajdos, C., Dardes, R.C., De Los Reyes, A., Park, W., Rademaker, A.W., and Jordan, V.C. (2002) Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice Journal of the National Cancer Institute 94: 274-283.

Liu, H., Park, W., Bentrem, D.J., McKian, K.P., de los Reyes, A., MacGregor Schafer, J., Zapf, J., and Jordan, V.C. (2002) Structure-function relationships of the raloxifene-estrogen receptor alpha complex for regulating transforming growth factor alpha expression in breast cancer cells. Journal of Biological Chemistry 277:9189-9198.

Dardes, R.C., O’Regan, R., Gajdos, C., Robinson, S.P., Bentrem, D., de los Reyes, A., and Jordan, V.C. (2002) Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clinical Cancer Research. 8:1995-2001.

Dardes, R.C., MacGregor Schafer, J., Timm Pearce, S., Osipo, C., Chen, B., and Jordan, V.C. (2002) Regulation of estrogen target genes and growth by selective estrogen receptor modulators in endometrial cancer cells. Gynecolgic Oncology. 85:498-506.

Levenson, A.S., Kliakhandler, I.L., Svoboda, K.M., Pease, K.M., Kaiser, S.A., Ward III, J.E., and Jordan, V.C. (2002) Molecular classification of oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha. British Journal of Cancer. 87:449-456.

Levenson, A.S., Svoboda, K.M., Pease, K.M., Kaiser, S.A., Chen, B., Simons, L.A., Jovanovic, B.D., Dyck, P.A., and Jordan, V.C. (2002) Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Research. 62:4419-4426.

de Lima, G.R., Facina, G., Shida, J.Y., Chein, M.B.C., Tanaka, P., Dardes, R.C., Jordan, V.C., and Gebrim,

L.H. (2003) Effect of low dose tamoxifen on the normal breast tissue of premenopausal women. European Journal of Cancer. 39:891-898.

Levenson, A.S., Gehm, B.D., Pearce, S.T., Horiguchi, J., Simons, L.A., Ward III, J.E., Jameson, J.L. and Jordan, V.C. (2003) Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER. International Journal of Cancer 104:587-596.

Pearce, S.T., Liu, H., and Jordan, V.C. (2003) Modulation of ER alpha function and stability by tamoxifen and a critical amino acid D538 in helix 12. Journal of Biological Chemistry. 278:7630-7638.

Tonetti, D.A., Rubenstein, R., DeLeon, M., Zhao, H., Pappas, S.G., Bentrem, D.J., Chen, B., Constantinou, A., and Jordan, V.C. (2003) Stable transfection of an estrogen receptor beta cDNA isoforms into MDA-MB-231 breast cancer cells. Journal of Steroid Biochemistry & Molecular Biology 87:47-55.

Liu, H., Lee E-S., Gajdos, C., Pearce, S.T., Chen, B., Osipo, C., Loweth, J., McKian, de los Reyes, A., and Jordan, V.C. (2003) Apoptotic action of 17 beta-estradiol in raloxifene resistant MCF-7 cells in vitro and in vivo. Journal of the National Cancer Institute 95:1586-1596.

Osipo, C., Gajdos, C., Liu, H., Chen, B., and Jordan, V.C. (2003) Paradoxical action of fulvestrant on estradiol-induced regression of tamoxifen-stimulated breast cancer. Journal of the National Cancer Institute 95:1597-1607.

Jensen, E.V. and Jordan, V.C. (2003) Dorothy P. Landon AACR Prize in Translational Research Lecture. “The Estrogen Receptor: a Model for Molecular Medicine. Clinical Cancer Research 9:1980-1989.

Bentrem, D., Fox, J.E., Pearce, S.T., Liu, H., Pappas, S., Kupfer, D., Zapf, J.W., and Jordan. V.C. (2003) Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Research 63: 7490-7496.

Jordan, V.C. (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines Part II: Clinical Considerations and New Agents. Journal of Medicinal Chemistry. 46 (7):1-31.

Pearce, S. T., Liu, H., Radhakrishnan, I., Abdelrahim, M., Safe, S., and Jordan, V. C. (2004) Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran (MCDF) with estrogen receptor. Cancer Research 64:2889-2897.

Mishra, S. K., Mazumdar, A., Vadlamudi, R.K., Li, F., Wang, R., Yu, W., Jordan, V. C.,
and Kumar, R. (2004) MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor alpha transactivation functions. Journal of Biological Chemistry 278: 19209-19219.

Lin, Y., Huang, R., Chen, L., Li, Shiyong, Shi, Q., Jordan, C., Huang, R. (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. International Journal of Cancer. 109:507-515.

Gehm, B.D., Levenson, A.S., Liu, H., Lee, E., Amundsen, B., Cushman, M., Jordan, V.C., and Jameson, J.L. (2004) Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. Journal of Steroid Biochemistry and Molecualr Biology. 88:223-234.
Tchou, J., Hou, N., Rademaker, A., Jordan, V.C. and Morrow, M. (2004) Acceptance of tamoxifen chemo prevention by physicans and women at risk. Cancer. 100:1800-1806Chen, B., Gajdos, C., Dardes, R., Kidwai, N., Johnston, S.R.D., Dowsett, M., and

Jordan, V.C. (2005) Potential of endogenous estrogen receptor beta to influence the selective ER modulator ER betac complex. International Journal of Oncology 27:327-35.

Jordan, V. C. (2004) Selective estrogen receptor modulation: Concept and consequences in cancer. Cancer Cell. 5:207-213.

Lewis, J.S., Osipo, C., Meeke, K. and Jordan, V.C. (2005) Estrogen induced apoptosis in a breast cancer model resistant to aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology 94:131-41.

Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer JM, Lee EJ, Jameson JL, Jordan VC, Cryns VL. (2004) PPARgamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. Journal of Biological Chemistry 280:6742-51

Kamradt MC, Lu M, Werner M, Kwan T, Feng C, Strohecker A, Oshita S, Wilkinson, JC, Yu C, Oliver PG,

Duckett CS, Buchsbaum DJ, LoBuglio AF, Jordan VC, Cryns VL (2005) The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3 Journal of Biological Chemistry 280:11059-66.

Chatterton R, Matteo ET, Hou N, Rademaker AF, Acharya S, Jordan VC, Morrow M. (2005) Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women. Journal of Endocrinology 186(1):77-84.